Life Sciences, Pharmaceutical, Drug Resistance, Kinase Inhibitors
Tuesday, May 11, 2021
10:00 a.m. EDT
Resistance development is all too common in cancer treatment and leads to cancer cells evading targeted therapies.
To better understand how these resistance mechanisms work and in order to help develop new therapies, Investigator Helma Simons–van Riel and her team at NTRC generated cell lines that acquired resistance to erdafitinib, an inhibitor that targets the fibroblast growth factor receptors (FGFRs) and is being used in the clinic. They then used these cell lines to identify the mechanism of resistance against erdafitinib.
In this webinar, Helma will discuss several factors that she and her team discovered that contribute to the development of resistance against erdafitinib. In addition, she will discuss other inhibitors they identified as potential therapeutic agents to overcome resistance.
Register for this webinar to learn more about how to unravel the acquired resistance mechanisms against targeted kinase inhibitors.
What You Will Learn:
- The mechanism of resistance to the FGFR inhibitor
- The varied ways that analysis tools such as qPCR and immunoblot, RNA sequencing, gene set enrichment analysis, proliferation assays, and next generation sequencing can offer insight
- Other inhibitors that may be used to overcome resistance against FGFR inhibitors
Who Should Attend?
- Research project leaders at pharmaceutical companies
- Small biotechnology companies
- Academic research institutions
Helma Simons–van Riel, Investigator Biology, NTRC